TELA Bio director gets 11,925 RSUs, option for 17,550 at $1.23

TELA Bio (TELA) reported a director equity grant.

Rhea-AI Filing Summary

TELA Bio (TELA) reported a director equity grant. On 10/31/2025, the reporting person acquired 11,925 shares of common stock at $0 (restricted stock units), bringing beneficial ownership of common stock to 11,925 shares, held directly.

The filing also shows a stock option for 17,550 shares at an exercise price of $1.23, expiring on 10/31/2035. The RSUs vest in three equal annual installments beginning 10/31/2026, and the option vests in 36 equal monthly installments starting 10/31/2025, in each case subject to continued service.

Insider Trade Summary

Grant/Award: 29,475 shares

Grant/Award 2 txns

Insider Plovanic William J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,550	$0.00	$0.00
Grant/Award	Common Stock	11,925	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,550 contracts (Direct); Common Stock — 11,925 shares (Direct)

Footnotes (2)

1. F1. These restricted stock units will vest in three equal annual installments beginning on October 31, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date.
2. F2. The option vests in 36 equal monthly installments on each monthly anniversary of October 31, 2025, in each case subject to the Reporting Person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TELA (TELA) disclose in this Form 4?

A director received 11,925 RSUs at $0 and a stock option for 17,550 shares at $1.23 on 10/31/2025.

How many RSUs were granted to the TELA director and how do they vest?

The grant was 11,925 RSUs, vesting in three equal annual installments beginning 10/31/2026, subject to continued service.

What are the terms of the stock option reported by TELA (TELA)?

An option for 17,550 shares at $1.23 per share, expiring on 10/31/2035, vesting in 36 equal monthly installments starting 10/31/2025.

What is the reporting person’s relationship to TELA Bio?

The reporting person is a Director of TELA Bio.

What is the ownership form of the reported holdings?

The holdings are reported as Direct (D) ownership.

How many common shares are beneficially owned after the transaction?

11,925 shares of common stock are beneficially owned following the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 04:22 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plovanic William J.

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MAVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/31/2025		A		11,925(1)	A	$0	11,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.23	10/31/2025		A		17,550		(2)	10/31/2035	Common Stock	17,550	$0	17,550	D

Explanation of Responses:

1. These restricted stock units will vest in three equal annual installments beginning on October 31, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date.

2. The option vests in 36 equal monthly installments on each monthly anniversary of October 31, 2025, in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Megan Smeykal, Attorney-in-Fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.